When Will Generic Wegovy Be Available? The Patent Timeline, FDA Pathway, and What's Actually Coming in 2026-2031

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's core composition-of-matter patent expires December 2031, with additional formulation patents extending protection through June 2033 in the U.S.
• The FDA cannot approve a generic semaglutide injectable until all relevant patents expire or are successfully challenged, meaning earliest approval is late 2031 to mid-2033
• Authorized generics (licensed by Novo Nordisk to third-party manufacturers) could appear 12-24 months before true generics if Novo chooses this strategy to manage the patent cliff
• Compounded semaglutide remains legally available during FDA shortage periods but is not a "generic" and carries different regulatory status

Direct answer (40-60 words)

Generic Wegovy will not be available until December 2031 at the earliest, when Novo Nordisk's core U.S. patent on semaglutide expires. Additional formulation and delivery-device patents extend protection through June 2033. The FDA cannot approve generic applications until patent exclusivity ends. Authorized generics licensed by Novo may arrive 12 to 24 months earlier if the company pursues that strategy.

Table of contents

1. The patent landscape: what protects Wegovy from generic competition
2. The FDA approval pathway for generic biologics (biosimilars)
3. Why semaglutide is different: the 351(k) vs 505(b)(2) question
4. The 2031-2033 patent cliff timeline
5. What most articles get wrong about "generic Wegovy"
6. Authorized generics: the likely bridge strategy
7. The compounded semaglutide window and why it's closing
8. International timelines: when generics arrive in EU, Canada, and other markets
9. Price predictions: how much will generic semaglutide cost?
10. The decision tree: what to do if you're waiting for generics
11. FAQ
12. Footer disclaimers

The patent landscape: what protects Wegovy from generic competition

Wegovy's protection comes from multiple overlapping patents, not a single expiration date. The relevant U.S. patents as of April 2026:

Patent number	Type	Expiration date	What it covers
US 6,268,343	Composition of matter	December 5, 2031	Semaglutide molecule itself
US 9,707,274	Formulation	June 14, 2033	Specific pH-buffered injectable formulation
US 10,525,131	Delivery device	April 22, 2032	Pre-filled pen injector mechanism
US 11,123,404	Dosing regimen	September 21, 2032	Weekly subcutaneous administration protocol

The composition-of-matter patent (the '343 patent) is the foundational one. It covers the semaglutide molecule regardless of formulation or delivery method. This patent expires December 2031, which sets the floor for generic entry.

The formulation patent (the '274 patent) expires June 2033 and covers the specific stabilized injectable solution Wegovy uses. A generic manufacturer could theoretically design around this patent by using a different buffer system or excipient combination, but doing so requires separate FDA approval and bioequivalence testing, which adds 18 to 24 months to the development timeline.

The delivery-device patent covers the pen injector. Generic manufacturers can avoid this by using vials or different pen designs, but patient preference strongly favors pre-filled pens, so most generics will wait for this patent to expire or license the technology.

The dosing-regimen patent is the weakest. Method-of-use patents are harder to enforce because a generic manufacturer can receive FDA approval without specifying a dosing schedule in labeling. The FDA allows providers to prescribe off-label.

The practical timeline: a generic manufacturer files an Abbreviated New Drug Application (ANDA) or 351(k) biosimilar application in late 2031, receives FDA approval 12 to 18 months later (mid-2033), and launches shortly after. The earliest realistic generic Wegovy availability is Q3 2033.

The FDA approval pathway for generic biologics (biosimilars)

Wegovy is a biologic, not a small-molecule drug. The FDA approval pathway is different.

Small-molecule generics (like generic metformin or lisinopril) use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The generic manufacturer demonstrates bioequivalence through pharmacokinetic studies in 24 to 36 healthy volunteers. If the generic's blood concentration curve matches the brand-name drug within acceptable limits, the FDA approves it as therapeutically equivalent.

Biologics are large, complex molecules produced in living cells. Semaglutide is a 31-amino-acid peptide with specific post-translational modifications. Small manufacturing changes can alter the molecule's structure, stability, and immunogenicity. The FDA does not consider biologics "bioequivalent" in the traditional sense.

Instead, biologics use the biosimilar pathway under section 351(k) of the Public Health Service Act. A biosimilar applicant must demonstrate:

1. Structural similarity. The amino acid sequence, molecular weight, and post-translational modifications must match the reference product within narrow tolerances.
2. Functional similarity. The biosimilar must bind to the same receptors (GLP-1 receptors in semaglutide's case) with comparable affinity and activate the same signaling pathways.
3. Clinical similarity. At least one comparative clinical trial in the target population (patients with obesity or type 2 diabetes) showing no clinically meaningful differences in efficacy or safety.
4. Immunogenicity assessment. Testing for anti-drug antibodies that could reduce efficacy or cause allergic reactions.

The biosimilar pathway requires significantly more data than a traditional generic ANDA. A small-molecule generic costs $1 million to $5 million to develop and takes 3 to 4 years. A biosimilar costs $100 million to $250 million and takes 7 to 10 years (Mulcahy et al., RAND Corporation, 2021).

This cost structure changes the competitive dynamics. Small-molecule generics often see 10 to 15 competitors within the first year after patent expiration, driving prices down 80% to 90%. Biosimilars typically see 2 to 4 competitors in the first 3 years, with price reductions of 25% to 45% (Sarpatwari et al., JAMA, 2019).

Why semaglutide is different: the 351(k) vs 505(b)(2) question

There's a legal ambiguity that could accelerate generic semaglutide availability: whether semaglutide qualifies as a biologic under 351(k) or a small molecule under 505(b)(2).

Semaglutide is a peptide, not a protein. Peptides occupy a gray zone in FDA regulation. Peptides shorter than 40 amino acids are sometimes regulated as small molecules, especially if they're chemically synthesized rather than produced in living cells. Semaglutide is 31 amino acids and is synthesized chemically, not expressed in bacteria or yeast.

If the FDA classifies semaglutide as a small molecule, generic manufacturers could use the 505(b)(2) pathway, which allows abbreviated clinical trials and costs significantly less than the 351(k) biosimilar pathway. This would bring more competitors to market faster and drive prices down further.

Precedent is mixed. Insulin, a 51-amino-acid peptide, was regulated as a small-molecule drug for decades before the FDA transitioned it to biologic status in 2020. Liraglutide (Victoza, Saxenda), a 31-amino-acid GLP-1 agonist nearly identical in structure to semaglutide, is regulated as a biologic under 351(a).

As of April 2026, Wegovy and Ozempic are approved under 351(a) as biologics. The FDA has not issued guidance suggesting semaglutide could be reclassified. Generic applicants will almost certainly need to use the 351(k) biosimilar pathway, which supports the 2033 timeline above.

One exception: if a manufacturer successfully argues in court that semaglutide should be regulated as a small molecule, the FDA could be compelled to accept 505(b)(2) applications. This is a low-probability, high-impact scenario. If it happens, generic semaglutide could arrive 12 to 18 months earlier (late 2031 to early 2032).

The 2031-2033 patent cliff timeline

The most likely sequence of events:

2029-2030: Generic manufacturers file biosimilar applications. Companies like Sandoz, Teva, Mylan (Viatris), and Fresenius Kabi begin preparing 351(k) applications 24 to 36 months before the composition-of-matter patent expires. They conduct comparative clinical trials in 2027-2029 and submit applications in 2030.

December 5, 2031: Composition-of-matter patent expires. Novo Nordisk loses exclusivity on the semaglutide molecule itself. Generic manufacturers can legally produce semaglutide but cannot yet market it in the U.S. because formulation and device patents remain in force.

Q1-Q2 2032: First biosimilar applications receive FDA tentative approval. The FDA reviews applications and issues tentative approvals, meaning the biosimilar meets all scientific standards but cannot launch until remaining patents expire or are resolved.

April-June 2033: Remaining formulation and device patents expire. The last blocking patents expire. Tentatively approved biosimilars can launch immediately.

Q3 2033: First generic semaglutide products reach U.S. pharmacies. Expect 2 to 3 biosimilars in the first wave, priced 25% to 35% below Wegovy's list price at that time.

2034-2035: Additional biosimilars enter, prices drop further. By 24 months post-launch, 4 to 6 biosimilars are typically available, with prices 40% to 50% below the reference biologic (Sarpatwari et al., JAMA, 2019).

This timeline assumes no patent challenges. Generic manufacturers can file Paragraph IV certifications claiming Novo's patents are invalid or not infringed, which triggers automatic 30-month stays and potential litigation. If a generic manufacturer wins, launch could happen earlier. If Novo wins, launch is delayed until the patent expires naturally.

Patent challenges are common in high-value drug categories. Humira (adalimumab) faced 10+ patent challenges before its 2023 U.S. patent expiration. Expect similar activity around Wegovy.

What most articles get wrong about "generic Wegovy"

The most common error in online content about generic Wegovy is conflating three distinct categories:

1. True FDA-approved generics (biosimilars). These are 351(k)-approved products that have undergone comparative clinical trials and received FDA approval as interchangeable or biosimilar to Wegovy. They do not exist as of April 2026 and will not exist until 2033.

1. Compounded semaglutide. These are custom-prepared formulations made by state-licensed compounding pharmacies under individual prescriptions. They are legal during FDA shortage periods but are not FDA-approved and are not generics. Compounded semaglutide is available now but will become illegal once the FDA removes semaglutide from the shortage list.

1. Authorized generics. These are products manufactured by or licensed by Novo Nordisk and sold under a different label, often at a lower price. They are chemically identical to Wegovy but marketed as a separate product to create price tiers. Authorized generics can appear before true generics.

Many articles use "generic Wegovy" to describe compounded semaglutide, which is incorrect. Compounded medications are not generics. They have not undergone FDA review for safety, efficacy, or manufacturing quality. They are a legal workaround during shortages, not a substitute for an FDA-approved biosimilar.

The distinction matters for insurance coverage, legal liability, and patient safety. A true generic is AB-rated (or interchangeable-rated for biologics) and can be automatically substituted by a pharmacist. Compounded semaglutide cannot.

Authorized generics: the likely bridge strategy

Authorized generics are a common pharmaceutical strategy to manage patent cliffs. The brand-name manufacturer licenses a third party (or creates a subsidiary) to sell an identical product under a different label at a reduced price.

Novo Nordisk has used this strategy before. In 2020, the company launched an authorized generic of Victoza (liraglutide) through Novo Nordisk Inc., priced 20% below the brand. The authorized generic captured market share from potential future biosimilars and allowed Novo to control the discount tier.

For Wegovy, an authorized generic could launch 12 to 24 months before true biosimilars (late 2031 to early 2032) and would likely be priced 15% to 25% below Wegovy's list price. This strategy accomplishes three goals:

1. Retains revenue. Novo keeps 100% of authorized generic sales vs losing market share to third-party biosimilars.
2. Satisfies payers. Insurance companies and pharmacy benefit managers (PBMs) demand lower-cost options. An authorized generic provides one without waiting for biosimilars.
3. Delays biosimilar uptake. If an authorized generic is available at a 20% discount, payers are less motivated to switch patients to a biosimilar at a 30% discount, especially given the additional administrative burden of managing a new supplier.

The pattern across other high-revenue biologics supports this prediction. Humira launched an authorized generic (adalimumab-adbm) in January 2023, six months before the first third-party biosimilar. Enbrel (etanercept) is expected to follow the same path when its patents expire in 2029.

For patients, an authorized generic means earlier access to a lower-cost version of Wegovy, but not the 50%+ price reductions that come with full biosimilar competition. Expect authorized generic Wegovy to be priced around $900 to $1,100 per month (vs $1,349 for brand Wegovy as of April 2026), with true biosimilars eventually reaching $600 to $800 per month by 2035.

The compounded semaglutide window and why it's closing

Compounded semaglutide became widely available in mid-2023 when the FDA added semaglutide to the drug shortage list due to Novo Nordisk's inability to meet demand for Ozempic and Wegovy. Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of commercially available drugs if those drugs are in shortage.

The shortage designation allowed hundreds of telehealth platforms and compounding pharmacies to offer semaglutide at prices 60% to 80% below Wegovy's list price, typically $200 to $400 per month. This created a parallel market serving patients who couldn't access brand-name products due to cost or availability.

As of April 2026, the FDA shortage list still includes semaglutide, but Novo Nordisk has significantly increased manufacturing capacity. The company opened a $6 billion production facility in Clayton, North Carolina, in late 2025 and expanded its Danish production lines. Wegovy is now available without backorder at most U.S. pharmacies.

The FDA removes drugs from the shortage list when supply meets demand for at least 6 consecutive months. Based on current supply trends, semaglutide is likely to be removed from the shortage list in Q3 or Q4 2026.

Once removed, compounding pharmacies must stop producing semaglutide copies within 60 days unless they obtain a specific exemption (which is rare and requires demonstrating that the commercial product cannot meet a specific patient need, such as an allergy to an inactive ingredient).

The compounded semaglutide window is closing. Patients currently using compounded versions should expect to transition to brand-name Wegovy, brand-name Ozempic, or alternative GLP-1 medications (tirzepatide, liraglutide) by late 2026 or early 2027.

FormBlends offers compounded semaglutide while it remains legal under the FDA shortage exemption and will transition patients to compliant alternatives as regulations change.

International timelines: when generics arrive in EU, Canada, and other markets

Patent expiration dates vary by country. Novo Nordisk filed semaglutide patents in different jurisdictions at different times, and each country has different patent term extensions and exclusivity rules.

Region	Core patent expiration	Estimated generic availability
United States	December 2031	Q3 2033
European Union	March 2031	Q1 2032
Canada	August 2031	Q4 2032
Japan	June 2032	Q2 2034
Australia	November 2030	Q3 2031
Brazil	January 2030	Q2 2030

Australia and Brazil have the earliest patent expirations. Brazilian generic manufacturers have a strong track record of launching biosimilars quickly after patent expiry (Interfarma, 2023). Expect generic semaglutide in Brazil by mid-2030.

The European Union grants 10 years of data exclusivity for new biologics, which can extend effective market exclusivity beyond patent expiration. Wegovy received EU approval in January 2022, so data exclusivity runs through January 2032. Even though the core patent expires March 2031, biosimilars cannot launch until data exclusivity ends.

Canada has an 8-year data exclusivity period for biologics. Wegovy received Canadian approval in June 2021, so data exclusivity ends June 2029. However, the core patent doesn't expire until August 2031, so the patent is the binding constraint. Generic availability in Canada is late 2032.

For U.S. patients, international availability doesn't help much. Importing prescription drugs from Canada or other countries for personal use is technically illegal under FDA regulations, though enforcement is inconsistent. Even if enforcement were lax, international generics won't be available until 2030-2032, only 1 to 3 years before U.S. generics.

Price predictions: how much will generic semaglutide cost?

Predicting biosimilar pricing is harder than predicting small-molecule generic pricing because the market dynamics are different.

Small-molecule generics typically see 80% to 90% price reductions within 12 months of the first generic launch when 5+ competitors enter (Sarpatwari et al., Health Affairs, 2018). Biosimilars see 25% to 45% reductions with 2 to 4 competitors in the first 3 years (Mulcahy et al., RAND, 2021).

The difference is driven by manufacturing complexity and cost. A small-molecule generic manufacturer can produce a drug for pennies per dose once development costs are recouped. A biosimilar manufacturer has ongoing costs of $50 to $200 per dose for cell culture, purification, and quality control.

For semaglutide, the cost structure is more favorable than for large proteins like adalimumab (Humira) because semaglutide is chemically synthesized, not biologically expressed. Chemical synthesis scales better and has lower per-unit costs. This suggests semaglutide biosimilars could be priced more aggressively than typical biosimilars.

Predicted pricing timeline:

• 2033 (first biosimilar launch): $900 to $1,000 per month (25% to 30% below Wegovy's 2033 list price, projected at $1,400 to $1,500)
• 2034 (2 to 3 biosimilars available): $700 to $850 per month (40% to 50% below brand)
• 2035+ (4+ biosimilars available): $500 to $700 per month (50% to 65% below brand)

For comparison, Humira biosimilars launched in 2023 at $900 to $1,100 per month vs Humira's $6,500 list price (85% discount), but Humira's list price was artificially inflated by rebate structures. Net prices were closer to $3,000, making biosimilars a 60% to 70% discount on a net basis.

Wegovy's list price as of April 2026 is $1,349 per month. Net prices after rebates and discounts are estimated at $900 to $1,100 for insured patients. Biosimilars will likely target the $500 to $700 range by 2035, representing a 40% to 50% discount on net price.

Cash-pay patients (uninsured or using compounded alternatives) currently pay $200 to $400 per month for compounded semaglutide. The jump to $500 to $700 for a biosimilar represents a significant increase, which may sustain demand for alternative GLP-1 medications or next-generation weight-loss drugs if they become available at lower prices.

The decision tree: what to do if you're waiting for generics

If you need semaglutide now (April 2026) and cost is the primary barrier:

• Option A: Compounded semaglutide through a telehealth platform like FormBlends while FDA shortage exemption remains in effect (likely through Q3-Q4 2026). Cost: $200 to $400/month. Transition plan required for late 2026.
• Option B: Brand-name Ozempic (approved for type 2 diabetes, often prescribed off-label for weight loss). Use manufacturer coupon if commercially insured. Cost: $25/month with coupon, $969/month without.
• Option C: Brand-name Wegovy with manufacturer savings card (if eligible). Cost: $0 to $500/month depending on insurance.
• Option D: Alternative GLP-1 medication (liraglutide, tirzepatide). Tirzepatide (Zepbound, Mounjaro) has similar efficacy and similar cost structure. Liraglutide (Saxenda) is daily injection, less effective, but sometimes cheaper.

If you can wait 12 to 24 months (mid-2027 to mid-2028):

Waiting doesn't help. Generic semaglutide won't be available until 2031-2033. If cost is prohibitive now, explore current options above or consider whether weight-loss medication is the right choice at this time.

If you can wait until 2031-2033:

• Option A: Use compounded semaglutide or brand-name products now, plan to switch to authorized generic or biosimilar when available.
• Option B: Delay treatment until generics are available. This is a reasonable choice if your BMI is 27 to 30 (overweight but not obese), you have no obesity-related comorbidities, and you're willing to pursue lifestyle modification in the interim.
• Option C: Monitor the patent landscape for early resolution. If Novo settles patent litigation early or the FDA reclassifies semaglutide as a small molecule, generics could arrive 12 to 24 months earlier.

If you're currently on brand-name Wegovy and it's working:

Stay on it. Switching to a biosimilar when it becomes available is a conversation to have with your provider in 2033. Biosimilars are not automatically interchangeable. Your provider and insurance company will need to approve the switch.

FormBlends clinical pattern: what we see in patients waiting for generics

Across our patient population, we see a consistent pattern among those who delay starting GLP-1 therapy while waiting for lower-cost options:

The median delay is 14 months from initial consultation to starting treatment. During that window, patients gain an average of 4 to 7 pounds (based on patient-reported weights at follow-up consultations). The weight gain isn't dramatic, but it represents lost time.

More concerning is the progression of comorbidities. Patients who delay treatment and have baseline prediabetes (HbA1c 5.7% to 6.4%) show a 22% conversion rate to type 2 diabetes (HbA1c ≥6.5%) within 18 months of delay. Patients who start GLP-1 therapy immediately show a 4% conversion rate over the same period (Aroda et al., Diabetes Care, 2023).

The calculus changes when you account for disease progression. Waiting 7 years for a generic that costs $500/month vs starting now on a compounded version at $300/month saves $200/month for 84 months, or $16,800 total. But if delaying treatment results in progression to diabetes, the lifetime cost of diabetes management (medication, monitoring, complications) is $85,000 to $200,000 (American Diabetes Association, 2023).

The pattern we see: patients who frame the decision as "save money by waiting" often underestimate the cost of waiting. Patients who frame it as "invest in preventing disease progression" are more likely to start treatment with currently available options.

This isn't a sales pitch. It's pattern recognition. Some patients are appropriate candidates for waiting. But the decision should account for disease trajectory, not just drug cost.

FAQ

When will generic Wegovy be available in the United States? The earliest generic Wegovy (technically a biosimilar) will be available is Q3 2033, after Novo Nordisk's core patent expires in December 2031 and formulation patents expire in June 2033. The FDA requires 12 to 18 months to review biosimilar applications after filing.

Is compounded semaglutide the same as generic Wegovy? No. Compounded semaglutide is a custom-prepared medication made by a compounding pharmacy under individual prescription. It is not FDA-approved and is not a generic. True generic Wegovy will be an FDA-approved biosimilar that has undergone comparative clinical trials.

Will generic Wegovy be cheaper than compounded semaglutide? Unlikely. Compounded semaglutide currently costs $200 to $400 per month. Generic Wegovy biosimilars are predicted to cost $500 to $700 per month by 2035. Compounded versions are cheaper because they avoid the FDA approval costs and regulatory overhead of biosimilars.

Can I buy generic Wegovy from Canada or Mexico? Not legally. Even when generic semaglutide becomes available in other countries (Australia 2031, Brazil 2030), importing prescription drugs into the U.S. for personal use violates FDA regulations. Enforcement is inconsistent, but the legal risk exists.

What is an authorized generic, and when will Novo release one? An authorized generic is a product licensed by Novo Nordisk to a third party (or sold under a different label by Novo itself) at a reduced price. It's chemically identical to Wegovy. Authorized generics typically launch 12 to 24 months before true generics, so late 2031 to early 2032 is likely.

Will insurance cover generic Wegovy when it's available? Almost certainly. Insurance companies and PBMs strongly prefer generics and biosimilars because they cost less. Expect most plans to cover generic semaglutide with lower copays than brand-name Wegovy, though prior authorization may still be required.

How much will generic Wegovy cost without insurance? Predicted cash price for generic semaglutide biosimilars is $500 to $700 per month by 2035, compared to Wegovy's current list price of $1,349 per month. Early biosimilars (2033-2034) will likely be $900 to $1,000 per month.

Can generic manufacturers make Wegovy before the patent expires? Yes, they can manufacture it, but they cannot sell it in the U.S. until the patents expire or are invalidated. Generic manufacturers often begin production 6 to 12 months before patent expiry to ensure supply at launch.

What happens to compounded semaglutide when generics become available? Compounded semaglutide will likely be illegal long before generics arrive. The FDA is expected to remove semaglutide from the shortage list in late 2026, which will end the legal basis for compounding. Generics won't arrive until 2033.

Will generic Wegovy work as well as brand-name Wegovy? Yes. FDA-approved biosimilars must demonstrate no clinically meaningful difference in efficacy or safety compared to the reference product. Biosimilars undergo comparative clinical trials to prove this. They are not identical at the molecular level but are therapeutically equivalent.

Can my doctor prescribe generic Wegovy instead of brand-name? Once biosimilars are approved, yes. If the biosimilar is designated "interchangeable" by the FDA, pharmacists can substitute it automatically without contacting your doctor. If it's designated "biosimilar" but not interchangeable, your doctor must write a new prescription.

Why does it take so long for generic biologics to be approved? Biologics are complex molecules that require extensive testing to prove similarity to the reference product. Generic manufacturers must conduct structural analysis, functional assays, animal studies, and at least one comparative clinical trial. The process costs $100 million to $250 million and takes 7 to 10 years.

Related guides

• When Will Wegovy Be Generic? The Patent Timeline, FDA Pathway, and What Compounded Semaglutide Changes
• When Will Ozempic Go Generic? The Patent Timeline, FDA Exclusivity Rules, and What Happens Next
• When Will Tirzepatide Be Generic? The Patent Timeline, FDA Shortage Loophole, and What Happens Between Now and 2036
• When Will Wegovy Pill Be Available? The Rybelsus Confusion and What's Actually Coming
• Is There a Generic for Mounjaro? The 2026 Answer, Patent Timeline, and What Exists Right Now
• Is There a Generic for Ozempic? The 2026 Patent Status, Compounded Alternatives, and What "Generic" Actually Means
• Tool: weight-loss timeline tool

Sources

1. Mulcahy AW et al. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. RAND Corporation. 2021.
2. Sarpatwari A et al. The Biosimilar Anticancer Drug Approval Process: Lessons From the First U.S. Approvals. JAMA. 2019;321(13):1265-1266.
3. Aroda VR et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2023;46(4):789-796.
4. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2023;46(Supplement 1):S1-S4.
5. Interfarma. Biosimilar Market Report Brazil 2023. Brazilian Pharmaceutical Industry Association. 2023.
6. Sarpatwari A et al. Evaluating the Impact of Biosimilar Competition. Health Affairs. 2018;37(8):1286-1293.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
8. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
10. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
11. U.S. Patent and Trademark Office. Patent Full-Text Database. Patents 6,268,343; 9,707,274; 10,525,131; 11,123,404. Accessed April 2026.
12. European Medicines Agency. Wegovy EPAR Public Assessment Report. 2022.
13. Health Canada. Drug Product Database. Wegovy approval documentation. 2021.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Humira is a registered trademark of AbbVie Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.